16
Treatment
Drug D
2
Antag D
2
PA D
3
5HT
1A
5HT
2A
Aripiprazole +++ +++ +++ ++
Asenapine +++ +++ ++ ++++
Clozapine + + + ++
Iloperidone +++ ++ ++ +++
Lurasidone +++ ? +++ ++
Olanzapine ++ ++ +++
Paliperidone +++ +++ + ++++
Quetiapine + + +* ++*
Risperidone +++ +++ + ++++
Ziprasidone +++ +++ ++ ++++
Therapeutic
Effects
Reduced positive
symptoms
Reduced
positive
symptoms
Reduced
positive
symptoms;
Reduced
negative
symptoms;
Procognitive;
Antidepressant
Reduced EPS;
Reduced
hyperprolactinemia;
Antidepressant;
Anxiolytic
Reduced EPS;
Reduced
hyperprolactinemia
Side Effects
EPS;
Hyperprolactinemia;
Increased negative
symptoms;
Increased negative
symptoms;
Increased cognitive
deficits; Sedation
Relatively
lower risk
of EPS
Unknown Unknown Cardiometabolic
+ weak binding affinity (100>Ki<1000)
++ moderate binding affinity (10>Ki<100)
+++ strong binding affinity (1>Ki<10)
++++ very strong binding affinity (Ki<1)
? No data yet available
* Binding property due primarily to the metabolite norquetiapine
Receptor Binding Profiles of Atypical Antipsychotics
